A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome

Kiaie, Nasim; Gorabi, Armita Mahdavi; Penson, Peter E.; Watts, Gerald F.; Johnston, Thomas P.; Banach, Maciej; Sahebkar, Amirhossein

doi:10.1016/j.drudis.2019.09.005

Cited by 31 publications

(18 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Large-artery atherosclerosis diseases are responsible for most of the IS cases, and atherosclerosis is the underlying process of the LAA subtype [5,40]. Notably, cIMT is a surrogate marker for the presence and progression of atherosclerosis [4], and the early detection of atherosclerosis using cIMT may help identify individuals at the risk for atherosclerotic IS [41]. Thus, our findings are of great importance for the prevention of IS, especially for LAA subtype.…”

Section: Discussionmentioning

confidence: 63%

Carotid Intima-Media Thickness, Genetic Risk, and Ischemic Stroke: A Family-Based Study in Rural China

Wang

et al. 2020

IJERPH

View full text Add to dashboard Cite

Background: Carotid intima-media thickness (cIMT) has been associated with an elevated risk of ischemic stroke (IS) in several studies, but the results are inconsistent. We investigated whether the association between cIMT and IS varied across different IS subtypes, and further assessed gene–cIMT interactions’ association with IS risk. Methods: A total of 1048 IS cases (795 large-artery atherosclerosis (LAA) cases, 103 small-vessel occlusion (SVO) cases, and 150 other subtypes) and 2696 IS-free controls across 2179 families were included in the analysis. Self-reported IS cases were confirmed through medical records’ review and head imaging by computed tomography and/or magnetic resonance imaging. The mean values of the common cIMT obtained in bilateral distal and proximal carotid artery segments were used. The genotype information of rs2910164 polymorphism in microRNA-146a (miR-146a) was also collected. Results: We found that cIMT was significantly associated with a higher risk of IS and LAA subtype but not SVO subtype in the multivariate-adjusted models. The odds ratio (OR) and 95% confidence interval (CI) in the highest quartile versus the lowest quartile of cIMT was 2.48 (1.92–3.20) for IS and 2.75 (2.08–3.64) for LAA (both p trend <0.001). The results also showed that there was a significant interaction between cIMT and rs2910164 genotype with the risk of IS (p interaction = 0.03) and LAA (p interaction = 0.02). The associations of cIMT with IS and LAA were strengthened among participants carried rs2910164_GG genotype compared with those with rs2910164_CC genotype. Conclusions: Our results indicate that higher cIMT levels were significantly associated with IS and LAA subtype but not SVO subtype, and the relations were modified by rs2910164 polymorphism in miR-146a.

show abstract

Section: Discussionmentioning

confidence: 63%

Carotid Intima-Media Thickness, Genetic Risk, and Ischemic Stroke: A Family-Based Study in Rural China

Wang

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…[ 82 ] Currently, more than 20 formulations are being studied in clinical trials or have been approved for clinical use. [ 83 ]…”

Section: Mitochondrial‐targeted Nps For the Treatment Of Ndsmentioning

confidence: 99%

Mitochondria‐targeted nanoparticles in treatment of neurodegenerative diseases

et al. 2021

View full text Add to dashboard Cite

Neurodegenerative diseases (NDs) are a class of heterogeneous diseases that includes Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Mitochondria play an important role in oxidative balance and metabolic activity of neurons; therefore, mitochondrial dysfunction is associated with NDs and mitochondria are considered a potential treatment target for NDs. Several obstacles, including the blood‐brain barrier (BBB) and cell/mitochondrial membranes, reduce the efficiency of drug entry into the target lesions. Therefore, a variety of neuron mitochondrial targeting strategies has been developed. Among them, nanotechnology‐based treatments show especially promising results. Owing to their adjustable size, appropriate charge, and lipophilic surface, nanoparticles (NPs) are the ideal theranostic system for crossing the BBB and targeting the neuronal mitochondria. In this review, we discussed the role of dysfunctional mitochondria in ND pathogenesis as well as the physiological barriers to various treatment strategies. We also reviewed the use and advantages of various NPs (including organic, inorganic, and biological membrane‐coated NPs) for the treatment and diagnosis of NDs. Finally, we summarized the evidence and possible use for the promising role of NP‐based theranostic systems in the treatment of mitochondrial dysfunction‐related NDs.

show abstract

“…Liposomes are biodegradable, biocompatible, nonimmunogenic, and possess a high loading capacity. With their amphiphilic nature, liposomes can deliver both hydrophilic (inside the core) and hydrophobic (embedded inside the phospholipid bilayer) drugs [69][70][71] . However, these particles have some shortcomings: instability, short blood circulation time, and insufficient drug loading capacity.…”

Section: Liposomesmentioning

confidence: 99%

Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer

Benko¹

2020

CDR

View full text Add to dashboard Cite

Cancer is one of the biggest healthcare concerns in our century, a disease whose treatment has become even more difficult following reports of drug-resistant tumors. When this happens, chemotherapy treatments fail or decrease in efficiency, leading to catastrophic consequences to the patient. This discovery, along with the fact that drug resistance limits the efficacy of current treatments, has led to a new wave of discovery for new methods of treatment. The use of nanomedicine has been widely studied in current years as a way to effectively fight drug resistance in cancer. Research in the area of cancer nanotechnology over the past decades has led to tremendous advancement in the synthesis of tailored nanoparticles with targeting ligands that can successfully attach to chemotherapy-resistant cancer by preferentially accumulating within the tumor region through means of active and passive targeting. Consequently, these approaches can reduce the off-target accumulation of their payload and lead to reduced cytotoxicity and better targeting. This review explores some categories of nanocarriers that have been used in the treatment of drug-resistant cancers, including polymeric, viral, lipid-based, metal-based, carbon-based, and magnetic nanocarriers, opening the door for an exciting field of discovery that holds tremendous promise in the treatment of these tumors.

show abstract

A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome

Cited by 31 publications

References 116 publications

Carotid Intima-Media Thickness, Genetic Risk, and Ischemic Stroke: A Family-Based Study in Rural China

Carotid Intima-Media Thickness, Genetic Risk, and Ischemic Stroke: A Family-Based Study in Rural China

Mitochondria‐targeted nanoparticles in treatment of neurodegenerative diseases

Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer

Contact Info

Product

Resources

About